

CORRECTION

Open Access



Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa

Laura Dixon^{1†}, Sara Bartel^{1†}, Victoria Brown¹, Sarrah I. Ali¹, Susan Gamberg^{1,2}, Andrea Murphy^{2,3}, Katherine L. Brewer⁴, Susan L. McElroy^{5,6}, Allan Kaplan⁷, Abraham Nunes^{2,8†} and Aaron R. Keshen^{1,2*†}

Correction: Journal of Eating Disorders (2023) 11:81
<https://doi.org/10.1186/s40337-023-00796-x>

The original article [1] has incomplete funding information. The sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge was not mentioned in the Funding note. The correct Funding note is as follows:

Funding

This work was supported by the Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry (Award No. 1023016). The Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry were not involved in the design of the study, data collection, analysis and interpretation, or in writing the manuscript. The article has received sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge.

The original article [1] has been corrected.

[†]Laura Dixon and Sara Bartel should be considered joint first author.

[†]Aaron R. Keshen and Abraham Nunes should be considered joint senior author.

The online version of the original article can be found at <https://doi.org/10.1186/s40337-023-00796-x>.

*Correspondence:

Aaron R. Keshen
aaron.keshen@nshealth.ca

¹ Eating Disorder Program, Nova Scotia Health Authority, Halifax, NS, Canada

² Department of Psychiatry, Dalhousie University, Halifax, NS, Canada

³ College of Pharmacy, Dalhousie University, Halifax, NS, Canada

⁴ College of Doctoral Studies, University of Phoenix, Tempe, AZ, USA

⁵ Lindner Center of HOPE, Mason, OH, USA

⁶ Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

⁷ Department of Psychiatry, Centre for Addiction and Mental Health, Institute of Medical Science, University of Toronto, Toronto, ON, Canada

⁸ Faculty of Computer Science, Dalhousie University, Halifax, NS, Canada

Published online: 16 November 2023

References

1. Dixon L, Bartel S, Brown V, et al. Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa. *J Eat Disord.* 2023;11:81. <https://doi.org/10.1186/s40337-023-00796-x>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

